Dec. 10, 2002 — Lansing, Mich., Dec. 10, 2002 – "Developing new and better therapies for osteoporosis and other bone diseases, Velcura Therapeutics, Inc. is interested in strategic partnerships to speed this process and bring the benefits in translating our scientific research from the laboratory bench to the bedside," said Dr. Michael W. Long, scientific founder and CEO of the biotechnology company that was honored at the Dec. 9 Michigan Investment and Commercialization Success Celebration.

Nov. 15, 2002 — ANN ARBOR, MICH., Nov. 15, 2002 – Dr. Michael W. Long, the scientific founder, president and chief executive officer of Velcura Therapeutics™, Inc., recently announced five staff additions at its new laboratory in Ann Arbor, Mich. The biotechnology company, which earlier this year received Michigan Life Sciences Corridor (MLSC) funding, recently was recognized by Chicago technology business magazine I-Street as being among the Midwest's top 50 emerging tech companies.

Sept. 18, 2002 — ANN ARBOR, MICH., Sept. 18, 2002 – The bad news was research showed smoking reduces the body’s ability to absorb calcium, damages cells, prevents new bone growth and can cause osteoporosis. Now here’s some good news. "Some of Michigan’s tobacco settlement money designated to energize the life sciences industry will enable our biotechnology company to expand its research into new therapies that stimulate bone formation rather than just stopping or delaying bone loss," said Dr. Michael Long, the founder, president and chief executive officer of Velcura Therapeutics™, Inc.